- Providing leadership for all NIAID research planning and implementation activities, including helping to prepare and support a strategic vision for NIAID
- Overseeing an extensive portfolio of basic, clinical, and applied research, as well as product development for biodefense, HIV/AIDS, infectious diseases, and immune-mediated disorders
His recent leadership activities include spearheading the development of the Institute’s strategic plan and chairing the NIAID Research Initiative Committee, an internal governance group that has designed and implemented a more efficient approach to planning, developing, and approving NIAID initiatives. Currently, Dr. Auchincloss is leading an NIAID initiative to design and implement changes in the Institute’s clinical research infrastructure, which will be flexible and available for domestic and international clinical research on HIV/AIDS and other infectious diseases. Additionally, Dr. Auchincloss is part of an NIAID senior leadership group responsible for reviewing all aspects of HIV/AIDS research policy, including the evaluation of “test and treat” strategies, analysis of results of pre-exposure prophylaxis (PrEP) clinical trials (including microbicide trials), and coordination of future HIV/AIDS vaccine clinical trials.
Dr. Auchincloss is active on many federal and NIH-wide committees, including the Trans-Federal Task Force on Optimizing Biocontainment Oversight, the National Security Strategy/Office of Science and Technology Policy on Optimizing Biological Select Agents and Toxins Working Group, and the National Biodefense Science Board. He recently was appointed as co-chair of the International Clinical Research Subcommittee of the NIH Global Health Research Working Group and as a member of the NIH Institute and Center Directors Clinical and Translational Science Awards Advisory Board. He also serves as the NIH point of contact for the Emergency Use Authorization program.
Dr. Auchincloss earned bachelor’s degrees in political science and economics and a master’s degree in economics from Yale University. He received his medical degree from Harvard Medical School in 1976.
Prior to his 2006 appointment at NIAID, Dr. Auchincloss was a transplant surgeon and professor of surgery at Harvard Medical School. For more than 17 years he operated a laboratory in transplantation immunology at Massachusetts General Hospital in Boston. In 1998, he founded the Juvenile Diabetes Research Foundation Center for Islet Transplantation and served as its director until 2003. He subsequently served as Chief Operating Officer of the NIAID Immune Tolerance Network.
In 2005, Dr. Auchincloss was elected president of the American Society of Transplantation. He has authored numerous scientific articles and texts and serves on the editorial boards of several major scientific publications.